Helen Stosel, MD
Endocrinology, Diabetes & Metabolism · Mission Viejo, CANPI 1952337362
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 29.5% of the total.
Across 140 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$645
- Novo Nordisk$392
- Abbott$348
- Lilly USA, LLC$110
- Insulet Corporation$102
- Amgen$62
- plus $526 from 19 others
What the payments were for
- Food & beverage$2,185100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $645 |
| Novo Nordisk | 25 | $392 |
| Abbott | 19 | $348 |
| Lilly USA, LLC | 7 | $110 |
| Insulet Corporation | 5 | $102 |
| Amgen | 3 | $62 |
| Dexcom, Inc. | 3 | $55 |
| Boehringer Ingelheim | 4 | $53 |
| Bayer | 2 | $46 |
| Medtronic | 2 | $40 |
| BETA Bionics, Inc. | 2 | $34 |
| Corcept Therapeutics | 1 | $31 |
| Ascendis Pharma Endocrinology Inc | 1 | $30 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| IBSA Pharma Inc. | 2 | $25 |
| Radius Health, Inc. | 1 | $24 |
| Mannkind Corporation | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Harmony Biosciences LLC | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Exact Sciences | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Cequr Corporation | 1 | $14 |
| Merck | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
How this compares
$2,185 in reported general payments places this provider in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 176 | $209,290 |
| MounjaroTirzepatide | 101 | $121,289 |
| JardianceEmpagliflozin | 53 | $68,873 |
| JanuviaSitagliptin Phosphate | 56 | $52,497 |
| SynthroidLevothyroxine Sodium | 319 | $30,982 |
| FarxigaDapagliflozin Propanediol | 25 | $30,268 |
| TrulicityDulaglutide | 27 | $29,609 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $27,045 |
| RybelsusSemaglutide | 15 | $25,377 |
| OmnitropeSomatropin | 12 | $22,108 |
| KerendiaFinerenone | 18 | $20,753 |
| Repatha SureclickEvolocumab | 18 | $19,187 |
| LinzessLinaclotide | 11 | $13,313 |
| Liothyronine Sodium | 243 | $8,079 |
| Levothyroxine Sodium | 362 | $4,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $392 | $234,667191 claims |
| Lilly USA, LLCMounjaro, Trulicity | $110 | $150,897128 claims |
| Boehringer IngelheimJardiance | $53 | $68,87353 claims |
| MerckJanuvia | $13 | $52,49756 claims |
| AbbVieSynthroid, Linzess, Armour Thyroid | $645 | $46,588365 claims |
| AstraZenecaFarxiga | $17 | $30,26825 claims |
| BayerKerendia | $46 | $20,75318 claims |
| IBSA Pharma Inc.Tirosint | $25 | $3,96616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Mission Viejo
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.